The glycolytic metabolism observed in P19 CSCs
is also linked with a drug-resistant phenotype. Thus, P19
CSCs were shown to be resistant to dichloroacetate, a
mitochondrial drug that reverses the abnormal metabolism
of cancer cells by shifting it from glycolysis to glucose
oxidation [23]. This mitochondria-mediated cell death
suppression seems to be a common feature among
different types of CSCs [33].